Company intelligence / Profile preview

Kiniciti

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Kiniciti does not develop therapeutics itself, so it has no clinical-stage drug programs or clinical results; instead, it invests in and builds operating companies (e.g., Ncardia, Cellistic) that provide enabling technologies and services for cell and gene therapy discovery, development, and manufacturing[1][2][3].

Modalities: Cell therapyGene therapy
Industry: Investors

Partnerships

Ncardia (strategic partnership and control stake; >$60M capital to build iPSC-based discovery and GMP cell therapy capabilities)[2]Welsh, Carson, Anderson & Stowe (up to $250M strategic capital commitment to Kiniciti)[3]Biospring Partners (equity investor and co-owner of the Kiniciti platform)[2][4]

Beyond the preview

Go deeper on Kiniciti.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kiniciti.

Explore the full profile